Krystal Biotech, Inc. $KRYS Shares Purchased by California State Teachers Retirement System

Key Points

• California State Teachers Retirement System increased its Krystal Biotech stake by 33,527.2% in the second quarter, acquiring 8.78 million additional shares and bringing its ownership to approximately 29.75%. Institutional investors and hedge funds collectively own 86.29% of the company.
• Krystal Biotech reported quarterly EPS of $1.79, beating estimates of $1.70, while revenue of $119.22 million fell slightly short of expectations. Analysts maintain a Moderate Buy consensus with an average price target of $365.40.
• KRYS shares opened at $345.55, down 0.7%, with a market capitalization of about $10.23 billion. Company insiders sold a combined 51,000 shares worth approximately $17.6 million over the past 90 days under pre-arranged trading plans.

California State Teachers Retirement System increased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 33,527.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,805,606 shares of the company's stock after purchasing an additional 8,779,420 shares during the quarter. California State Teachers Retirement System owned approximately 29.75% of Krystal Biotech worth $3,272,780,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in KRYS. Silvant Capital Management LLC purchased a new stake in shares of Krystal Biotech during the second quarter worth $30,000. Western Wealth Management LLC acquired a new stake in shares of Krystal Biotech in the first quarter valued at about $34,000. Greenline Wealth Management LLC purchased a new position in shares of Krystal Biotech in the fourth quarter worth about $34,000. UMB Bank n.a. lifted its stake in shares of Krystal Biotech by 34.6% in the fourth quarter. UMB Bank n.a. now owns 144 shares of the company's stock worth $36,000 after buying an additional 37 shares in the last quarter. Finally, Global Retirement Partners LLC boosted its position in Krystal Biotech by 788.9% during the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company's stock worth $39,000 after acquiring an additional 142 shares during the last quarter. 86.29% of the stock is owned by institutional investors and hedge funds.

Krystal Biotech Trading Down 0.7%

Shares of KRYS stock opened at $345.55 on Friday. Krystal Biotech, Inc. has a twelve month low of $137.02 and a twelve month high of $382.54. The company's 50-day moving average price is $347.95 and its 200-day moving average price is $309.76. The stock has a market cap of $10.23 billion, a price-to-earnings ratio of 43.30 and a beta of 0.54.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.70 by $0.09. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. The firm had revenue of $119.22 million during the quarter, compared to analysts' expectations of $120.93 million. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 7.48 EPS for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Chardan Capital raised shares of Krystal Biotech to a "strong-buy" rating in a research note on Monday, August 3rd. Weiss Ratings lowered shares of Krystal Biotech from a "buy (b)" rating to a "buy (b-)" rating in a research note on Tuesday, August 18th. HC Wainwright boosted their target price on Krystal Biotech from $310.00 to $361.00 and gave the stock a "buy" rating in a report on Tuesday, June 16th. Jefferies Financial Group restated a "buy" rating and set a $474.00 target price on shares of Krystal Biotech in a report on Monday, July 13th. Finally, Wall Street Zen lowered Krystal Biotech from a "buy" rating to a "hold" rating in a research report on Saturday, June 20th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $365.40.

Insider Activity

In other news, EVP John Thomas sold 1,000 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the completion of the sale, the executive vice president owned 1,000 shares of the company's stock, valued at $347,270. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the sale, the insider owned 1,302,145 shares of the company's stock, valued at $467,886,741.40. This represents a 1.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 51,000 shares of company stock valued at $17,558,270 in the last 90 days. Company insiders own 13.10% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company uses engineered herpes simplex virus type 1 (HSV-1) vectors to deliver functional genes to targeted tissues, with an emphasis on treatments that can be administered directly to affected areas.

Krystal Biotech's lead product is Vyjuvek (beremagene geperpavec-svdt), a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited disorder that causes fragile skin and recurrent blistering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.